Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 16/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487200 | 0.93 | DHODH (0.40) | DHODHTSHRHSD17B10ALDH1A1TP53 | |
| SCHEMBL3486973 | 0.91 | ADORA2B (0.39) | DHODHALDH1A1KDM4ETP53 | |
| SCHEMBL4466726 | 0.91 | MAPT (0.36) | DHODHTSHRHSD17B10KDM4ETP53 | |
| SCHEMBL3486976 | 0.84 | ADORA2B (0.40) | DHODHALDH1A1TP53LMNA | |
| SCHEMBL4486724 | 0.76 | BTK (0.36) | DHODHHSD17B10ALDH1A1KDM4ELMNA | |
| SCHEMBL3488025 | 0.72 | ALDH1A1 (0.44) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL4486723 | 0.71 | BTK (0.36) | DHODHHSD17B10ALDH1A1KDM4ELMNA | |
| SCHEMBL3486901 | 0.71 | SMN1; SMN2 (0.38) | ALDH1A1KDM4ETP53LMNAKMT2A | |
| SCHEMBL3487865 | 0.70 | SMN1; SMN2 (0.35) | TSHRHSD17B10TP53KMT2A | |
| SCHEMBL3488389 | 0.70 | SMN1; SMN2 (0.35) | TSHRHSD17B10TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | claimed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | claimed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | DHODH 2862/4885TSHR 540/4885HSD17B10 223/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | DHODH 2829/4885TSHR 523/4885HSD17B10 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.